Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing
approximately 85% of cases. The diagnosis is often made in the middle and late stages …

Simple Summary Hepatocellular carcinoma (HCC) is the most common primary hepatic
malignancy, with increasing incidence over the past several decades. The majority of …

Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common
form of liver cancer, remains a major public health problem worldwide. The immune …

Hepatocellular carcinoma (HCC) is an important cause of cancer death and is considered
the 3rd most lethal around the world. Hepatectomy, liver transplantation, and ablation …

The absence of potent therapeutic option accounts for the dismal prognosis of advanced
hepatocellular carcinoma (HCC) with high mortality and recurrence rate. For a decade …

The implementation of immune checkpoint inhibitors (ICI) into the clinical management of
different malignancies has largely changed our understanding of cancer treatment. After …

Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …

Simple Summary Liver cancer is one of the most devastating human malignancies
worldwide, especially in Asia, where over 70% of new cases are diagnosed. Most liver …

Simple Summary Advanced hepatocellular carcinoma (HCC) carries a grim prognosis,
which has historically been compounded by a lack of available systemic therapies …

Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced
hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune …